Jason Jean

  1. Home
  3. University of Saskatchewan
  4. Jason Jean
Jason Jean

Jason Jean

  • Courses5
  • Reviews19
Rate This Professor

Social Profile:

Join to see

Biography

University of Saskatchewan - Sociology


Experience

  • The National Institutes of Health

    Staff Scientist

    Jason worked at The National Institutes of Health as a Staff Scientist

  • University of Manitoba

    Assistant Professor

    Department of Medical Microbiology and Infectious Diseases

  • National Institutes of Health - National Institute of Allergy and Infectious Disease

    Visiting Fellow

    Jason worked at National Institutes of Health - National Institute of Allergy and Infectious Disease as a Visiting Fellow

  • Centre for Microbial Diseases and Immunity Research - UBC

    postdoctoral fellow

    Jason worked at Centre for Microbial Diseases and Immunity Research - UBC as a postdoctoral fellow

  • Battelle

    Principle Research Scientist - Biochemist

    Jason worked at Battelle as a Principle Research Scientist - Biochemist

Education

  • University of Saskatchewan

    Doctor of Philosophy (Ph.D.)



  • University of Saskatchewan

    PhD

    Biochemistry

Publications

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

    Antimicrobial agents and chemotherapy

    Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

    Antimicrobial agents and chemotherapy

    Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

    Antimicrobial agents and chemotherapy

    Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

  • Ebola Virion Attachment and Entry into Human Macrophages Profoundly Effects Early Cellular Gene Expression

    Public Library of Science

    Wahl-Jensen, Victoria, Sabine Kurz, Friedericke Feldmann, Lukas K. Buehler, Jason Kindrachuk, Victor DeFilippis, Jean da Silva Correia, Klaus Früh, Jens H. Kuhn, Dennis Burton, and Heinz Feldmann. 2011. Ebola Virion Attachment and Entry into Human Macrophages Profoundly Effects Early Cellular Gene Expression. PLoS Neglected Tropical Diseases (San Francisco) 5(10):e1359

  • ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick

    MDPI, Basel, Switzerland

    Lackemeyer, Matthew G., Fabian de Kok-Mercado, Jiro Wada, Laura Bollinger, Jason Kindrachuk, Victoria Wahl-Jensen, Jens H. Kuhn, and Peter B. Jahrling. 2014. ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick. Viruses (Basel) 6(1): 137-150 [Epub Dec. 7, 2014]. PMID: 24402304.

  • The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis

    American Society for Microbiology (ASM), Washington, DC, USA

    Kindrachuk, Jason, Britini Ork, Brit J. Hart, Steven Mazur, Michael R. Holbrook, Matthew B. Frieman, Dawn Traynor, Reed F. Johnson, Julie Dyall, Jens H. Kuhn, Gene G. Olinger, Lisa E. Hensley, and Peter B. Jahrling. 2014. The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome Analysis. Antimicrobial Agents and Chemotherapy (Washington, DC) [Epub Dec. 8, 2014].

  • Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

    Antimicrobial agents and chemotherapy

    Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.

  • Ebola Virion Attachment and Entry into Human Macrophages Profoundly Effects Early Cellular Gene Expression

    Public Library of Science

    Wahl-Jensen, Victoria, Sabine Kurz, Friedericke Feldmann, Lukas K. Buehler, Jason Kindrachuk, Victor DeFilippis, Jean da Silva Correia, Klaus Früh, Jens H. Kuhn, Dennis Burton, and Heinz Feldmann. 2011. Ebola Virion Attachment and Entry into Human Macrophages Profoundly Effects Early Cellular Gene Expression. PLoS Neglected Tropical Diseases (San Francisco) 5(10):e1359

112

3(1)

  • Level:
  • Credit hours: 0

SOC 112

2.6(11)

  • Level:
  • Credit hours: 0

SOC 212

3.8(4)

  • Level:
  • Credit hours: 0

SOC 214

2.5(2)

  • Level:
  • Credit hours: 0

SOCIOLOGY 1

2.5(1)

  • Level:
  • Credit hours: 0
Load More